These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 38791206)

  • 1. Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer's Disease.
    Li J; Haj Ebrahimi A; Ali AB
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
    Parsons C; Lim WY; Loy C; McGuinness B; Passmore P; Ward SA; Hughes C
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD009081. PubMed ID: 35608903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease.
    Kashif M; Sivaprakasam P; Vijendra P; Waseem M; Pandurangan AK
    Curr Pharm Des; 2023; 29(43):3428-3441. PubMed ID: 38038007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms.
    Brendel M; Sauerbeck J; Greven S; Kotz S; Scheiwein F; Blautzik J; Delker A; Pogarell O; Ishii K; Bartenstein P; Rominger A;
    J Alzheimers Dis; 2018; 65(3):793-806. PubMed ID: 30010116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Challenge of Antidepressant Therapeutics in Alzheimer's Disease.
    Lozupone M; La Montagna M; D'Urso F; Piccininni C; Rinaldi A; Beghi M; Cornaggia CM; Sardone R; Solfrizzi V; Daniele A; Seripa D; Giannelli G; Bellomo A; Panza F
    Adv Exp Med Biol; 2020; 1260():267-281. PubMed ID: 32304037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of cognitive decline in healthy aging based on neuropsychiatric symptoms and PET-biomarkers of Alzheimer's disease.
    Ronat L; Hanganu A; Chylinski D; Van Egroo M; Narbutas J; Besson G; Muto V; Schmidt C; Bahri MA; Phillips C; Salmon E; Maquet P; Vandewalle G; Collette F; Bastin C
    J Neurol; 2024 Apr; 271(4):2067-2077. PubMed ID: 38114820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.
    O'Brien JT; Holmes C; Jones M; Jones R; Livingston G; McKeith I; Mittler P; Passmore P; Ritchie C; Robinson L; Sampson EL; Taylor JP; Thomas A; Burns A
    J Psychopharmacol; 2017 Feb; 31(2):147-168. PubMed ID: 28103749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylcholinesterase inhibition in Alzheimer's Disease.
    Ibach B; Haen E
    Curr Pharm Des; 2004; 10(3):231-51. PubMed ID: 14754384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential therapeutic natural products against Alzheimer's disease with Reference of Acetylcholinesterase.
    Ahmed S; Khan ST; Zargaham MK; Khan AU; Khan S; Hussain A; Uddin J; Khan A; Al-Harrasi A
    Biomed Pharmacother; 2021 Jul; 139():111609. PubMed ID: 33915501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease.
    Levy ML; Cummings JL; Kahn-Rose R
    Gerontology; 1999; 45 Suppl 1():15-22. PubMed ID: 9876214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depression in Alzheimer's Disease: An Alternative Role for Selective Serotonin Reuptake Inhibitors?
    Elsworthy RJ; Aldred S
    J Alzheimers Dis; 2019; 69(3):651-661. PubMed ID: 31104017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression: a meta-analysis of depression and cognitive outcomes.
    Sepehry AA; Lee PE; Hsiung GY; Beattie BL; Jacova C
    Drugs Aging; 2012 Oct; 29(10):793-806. PubMed ID: 23079957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (-)-P7C3-S243 Protects a Rat Model of Alzheimer's Disease From Neuropsychiatric Deficits and Neurodegeneration Without Altering Amyloid Deposition or Reactive Glia.
    Voorhees JR; Remy MT; Cintrón-Pérez CJ; El Rassi E; Khan MZ; Dutca LM; Yin TC; McDaniel LN; Williams NS; Brat DJ; Pieper AA
    Biol Psychiatry; 2018 Oct; 84(7):488-498. PubMed ID: 29246437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimer's disease.
    Popp J; Arlt S
    Curr Opin Psychiatry; 2011 Nov; 24(6):556-61. PubMed ID: 21934621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholinesterase inhibitors as Alzheimer's therapeutics (Review).
    Sharma K
    Mol Med Rep; 2019 Aug; 20(2):1479-1487. PubMed ID: 31257471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.